Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Drug Could Be First Of Wave Of Nucleic Medicines Approved In Japan

This article was originally published in PharmAsia News

Executive Summary

Biotechnology methods of finding new ways to fight diseases are part of a growing business move in Japan as major drug makers take a nucleic-acid approach to drugs. The new treatment strategy is expected to reach a milestone when Pfizer receives approval from the Health Ministry for its age-related macular degeneration drug Macugen (pegaptanib), probably later this month. The drug relies on aptamers, synthetic molecules of a certain shape to bind better with targeted proteins. The head of Ribomic, a Tokyo bioventure, said approval of Macugen is likely to spur development in Japan. (Click here for more - a subscription may be required

You may also be interested in...



QUOTED. 28 October 2020. Serge Bernasconi.

A new report focused on the European market says that winning trust is the key to taking AI adoption to the next stage. That approach was praised by MedTech Europe CEO Serge Bernasconi.

Brexit To Bring Regulatory Duplication, Possible Disruptions For UK Cosmetics Interests

As the transition period following the UK’s withdrawal from the European Union draws to a close, cosmetics industry stakeholders are following final trade negotiations while readying themselves for new regulatory complexities.

The Future Of Purdue: Will The ‘Public Benefit Corporation’ Model Take Off?

Purdue’s opioid settlement is making headlines for the size of the financial penalty. But the plan to re-imagine Purdue as a public benefit company could have far-reaching significance for the industry – if it ever gets off the ground.

UsernamePublicRestriction

Register

OM000882

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel